Isturisa (Osilodrostat Phosphate) Patent Expiration, LOE Window & CMS Spending

Isturisa (Osilodrostat Phosphate) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2033-05-20 (last listed 2035-10-12), 0 AB generics, $82.6M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRecordati Rare Diseases
FDA Application & PathwayN212801 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-05-20
Last Listed Patent or Exclusivity Date2035-10-12
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$82.6M
2024 Medicare Part D Spend$65.5M
2024 Medicaid Spend$17.1M
Reported Wholesale Price Change (CA SB 17)16 WAC filings (max 103.5% 2-yr change)